image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Data provided by Kaleidoscope.